Soliris Concentrate for Solution for Infusion
Eculizumab
300 mg
Alexion Pharma International Operations Unlimited Company
| Pack size | 1 Vial (30 ml) |
|---|---|
| Dispensing mode | |
| Source | |
| Agent | |
| Retail Price | 15227.15 AED |
Indications
Soliris Concentrate for Solution for Infusion is used for:
Eculizumab is indicated to treat paroxysmal nocturnal hemoglobinuria (PNH) to reduce hemolysis, atypical hemolytic uremic syndrome to inhibit complement-mediated thrombotic microangiopathy[L6919,A2246], and neuromyelitis optica spectrum disorder (NMOSD).[L6916]
Adult Dose
Child Dose
Renal Dose
Administration
Contra Indications
Precautions
Pregnancy-Lactation
Interactions
Adverse Effects
Side effects of Eculizumab :
Mechanism of Action
Eculizumab is a monoclonal antibody that targets complement protein C5, preventing cleavage to C5a and C5b, and the formation of the terminal complement complex C5b-9.[L6919,A2245,A2246] Inhibition of this complex prevents complement mediated intravascular hemolysis in paroxysmal nocturnal hemoglobunuria, complement mediated microangiopathy in atypical hemolytic uremic syndrome, and immune mediated inflammation and damage of the central nervous system in neuromyelitis optica spectrum disorder.[L6919,L6916,A2246]
Note
Soliris 300 mg Concentrate for Solution for Infusion manufactured by Alexion Pharma International Operations Unlimited Company. Its generic name is Eculizumab. Soliris is availble in Saudi Arabia.
Farmaco SA drug index information on Soliris Concentrate for Solution for Infusion is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.